By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...
More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.
These data, as well as new pre-clinical data from IO Biotech’s second vaccine candidate, IO112, will be presented at the Society for Immunotherapy of Cancer’s 39th Annual Meeting in Houston on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback